Revue du Rhumatisme (Edition Francaise)最新文献

{"title":"Conséquences économiques des lombalgies chroniques","authors":"Bernard Fouquet ,&nbsp;Laure Trehorel","doi":"10.1016/j.rhum.2024.06.015","DOIUrl":"10.1016/j.rhum.2024.06.015","url":null,"abstract":"<div><div>La lombalgie chronique, affection hétérogène, est le problème de santé le plus important dans tous les pays du monde. Il semble être le plus coûteux non seulement à cause des coûts de santé mais surtout en termes de coûts sociétaux. Ces coûts sociétaux sont non seulement supportés par les employeurs mais aussi par le patient et sa famille. Les coûts induits représentent classiquement 1 à 2 % du produit intérieur brut. Les coûts liés à la perte de productivité représentent plus de 50 % des coûts totaux. Une évidence croissante provient du fait que des traitements décevants sont associés à une augmentation de solutions coûteuses, principalement chirurgicales. Toutefois, la complexité d’évaluer les coûts associés à la difficulté de mesurer la complexité des situations chroniques et d’évaluer la qualité de vie conduit généralement à des évaluations partielles des coûts directs et indirects, des ratios coûts/utilité et coûts/efficacité qui sont nécessaires pour les évaluations économiques des traitements.</div></div><div><div>Non specific chronic low back pain, heterogeneous disorder, is one of the most common health problems over all countries around the world. It seems to be the most expansive in terms of health care costs but mainly in terms of societal costs. These societal costs are not only supported by the employers but also by the patient his family. It is classically 1–2% of the gross national product (<em>produit intérieur brut</em>). Costs arising from productivity loss account for more than 50% of the total costs. Growing evidence come from the fact that disappointing treatment results are associated to an increase of expansive solutions mainly associated to an increase of surgical procedures. Though, the complexity of assessing the costs associated to the difficulty to evaluate the chronical back pain states and to assess to the complexity of quality of life makes generally partial evaluations of the direct and indirect costs, costs/utility ratio and the costs/effectiveness ratio that are necessary for the economic evaluation of the treatments.</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 5","pages":"Pages 642-652"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141707161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Douleur","authors":"Claire Guillot","doi":"10.1016/j.rhum.2024.07.006","DOIUrl":"10.1016/j.rhum.2024.07.006","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 5","pages":"Pages 549-552"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidités et facteurs pronostiques de la maladie de Sjögren","authors":"","doi":"10.1016/j.rhum.2024.05.012","DOIUrl":"10.1016/j.rhum.2024.05.012","url":null,"abstract":"&lt;div&gt;&lt;div&gt;La maladie de Sjögren est une affection auto-immune complexe qui persiste à poser d’importants défis malgré les progrès de la recherche. Il s’agit d’une maladie rare dont la prévalence est estimée entre 0,01 % et 0,05 %. Son incidence est variable selon les pays mais pourrait être en augmentation sur les deux dernières décennies. Les facteurs de risque, incluant les antécédents familiaux, le stress et les expositions hormonales, demeurent incomplètement élucidés. La maladie de Sjögren peut coexister avec d’autres maladies auto-immunes en particulier avec les thyroïdites auto-immunes, la polyarthrite rhumatoïde, le lupus érythémateux systémique et la sclérodermie systémique. C’est la maladie auto-immune au cours de laquelle l’augmentation du risque de lymphome est la plus importante. Il pourrait également y avoir, comme au cours d’autres maladies auto-immunes telles que la polyarthrite rhumatoïde ou le lupus, une augmentation du risque cardiovasculaire, bien que les preuves à ce sujet restent à consolider. Les recherches actuelles révèlent l’existence de divers sous-groupes de patients, définis par leurs symptômes, leurs paramètres clinico-biologiques, et/ou leur origine géographique. Cette variabilité est à l’origine de profils évolutifs différents et d’un risque de mortalité très fortement influencé par la présence ou non de lymphome, la survenue ce dernier étant particulièrement lié à l’activité systémique de la maladie. Cette revue générale abordera les bases épidémiologiques, l’hétérogénie phénotypique et pronostique soulignant la nécessité d’une approche thérapeutique individualisée au cours de la maladie de Sjögren.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Sjögren disease is a complex autoimmune disorder with ongoing challenges despite research advances. It is a rare disease with an estimated prevalence between 0.01% and 0.05%. Its incidence varies by country but could be increasing over the last two decades. Risk factors, including family history, stress, and hormonal exposures, remain incompletely understood. Sjögren disease can coexist with other autoimmune diseases, particularly autoimmune thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. It is the autoimmune disease with the highest increased risk of lymphoma. There may also be, as in other autoimmune diseases such as rheumatoid arthritis or lupus, an increased risk of cardiovascular disease, although evidence remains to be consolidated. Current research reveals the existence of various patient subgroups, defined by their symptoms, clinical presentation, biological parameters, and/or geographic origin. This variability leads to different evolutionary profiles and a risk of mortality strongly influenced by the presence or absence of lymphoma, the occurrence of which is particularly linked to the systemic activity of the disease. This general review will address the epidemiological foundations, phenotypic and prognostic heterogeneity, highlighting the nee","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 5","pages":"Pages 608-616"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141392033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiopathologie (partie 2) – session « Rhumatologues en formation »","authors":"Margaux Moret","doi":"10.1016/j.rhum.2024.08.012","DOIUrl":"10.1016/j.rhum.2024.08.012","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 5","pages":"Pages 596-601"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L’évolution des prescriptions en rhumatologie : un regard à travers la pharmaco-épidémiologie","authors":"","doi":"10.1016/j.rhum.2024.05.003","DOIUrl":"10.1016/j.rhum.2024.05.003","url":null,"abstract":"<div><div>L’évolution des prescriptions en rhumatologie reflète un domaine médical en constante mutation, où les avancées scientifiques et les progrès technologiques redéfinissent les pratiques cliniques. Les médicaments anti-inflammatoires (AINS ou corticoïdes), autrefois largement prescrits pour soulager la douleur et l’inflammation, sont maintenant utilisés avec prudence en raison de leurs effets secondaires. L’arrivée des thérapies ciblées a offert des perspectives d’épargne médicamenteuse, mais a également soulevé des points de vigilance spécifique concernant leur tolérance. Les études pharmaco-épidémiologiques bien conçues peuvent fournir des données précieuses sur l’utilisation des médicaments dans des conditions réelles, éclairant ainsi les décisions de prescription, les politiques de remboursement et les choix thérapeutiques.</div></div><div><div>The trend in rheumatology prescriptions reflects an ever-changing medical field, where scientific advances and technological progress are reshaping clinical practices. Anti-inflammatory drugs (NSAIDs or corticoids), once widely prescribed to relieve pain and inflammation, are now used with caution due to their side effects. The development of targeted therapies has opened up the prospect of drug savings, but has also raised specific points of concern regarding their safety. Well-designed pharmaco-epidemiological studies can provide valuable data on drug use in real-life conditions, informing prescribing decisions, reimbursement policies and treatment alternatives.</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 5","pages":"Pages 635-641"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Le Système national des données de santé pour évaluer les traitements ciblés : exemple du rhumatisme psoriasique","authors":"Laura Pina Vegas ,&nbsp;Pascal Claudepierre ,&nbsp;Emilie Sbidian","doi":"10.1016/j.rhum.2024.05.008","DOIUrl":"10.1016/j.rhum.2024.05.008","url":null,"abstract":"<div><div>Le Système national des données de santé (SNDS) est un entrepôt de bases de données médico-administratives qui rassemble les informations issues des remboursements de soins de ville et des établissements de santé, ainsi que les causes médicales de décès de près de 99 % de la population française. En fournissant des données exhaustives médicales sur une large population, non sélectionnée, « en vraie vie », et sans perte de suivi, le SNDS a ouvert la voie à de nombreuses études épidémiologiques et pharmacoépidémiologiques, incluant la prise en charge thérapeutique des pathologies inflammatoires chroniques. Cet article explore en détail les divers types de variables disponibles dans cette base, ainsi que les méthodes statistiques pertinentes pour exploiter ces données. Il illustre ces points à travers l’exemple de l’étude des traitements ciblés du rhumatisme psoriasique. Les limites du SNDS sont également exposées, accompagnées d’exemples de mesures prises pour minimiser les biais potentiels inhérents aux études qui en découlent. Ainsi, cet article fournit des informations pratiques afin d’améliorer la compréhension et l’utilisation de cette base de données unique.</div></div><div><div>The French Health Insurance database (<em>Système national des données de santé:</em> SNDS) is a repository of healthcare administrative databases containing information on reimbursements for outpatient care and healthcare establishments, as well as medical causes of death for nearly 99% of the French population. By furnishing comprehensive medical data on a large, unselected population in “real-life” conditions, and with no loss of follow-up, the SNDS has paved the way for numerous epidemiological and pharmacoepidemiological studies, including the therapeutic management of chronic inflammatory diseases. This article delves into the various types of variables available in this database, along with the relevant statistical methods to exploit this data. It illustrates these points with the example of studying targeted therapies for psoriatic arthritis. The limitations of the SNDS are also outlined, accompanied by examples of measures taken to minimize potential biases inherent in resulting studies. Thus, this article provides practical information to enhance the understanding and use of this unique database.</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 5","pages":"Pages 625-634"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Le niveau initial de protéine C réactive : un élément de choix discriminant entre anti-TNF et anti-IL17 en premier traitement biologique ciblé de la spondyloarthrite axiale ?","authors":"Philippe Goupille ,&nbsp;Daniel Wendling","doi":"10.1016/j.rhum.2023.12.005","DOIUrl":"10.1016/j.rhum.2023.12.005","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 4","pages":"Pages 436-440"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139017265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ce mois-ci dans Joint Bone Spine 2024 (Juillet);91/4","authors":"Marie-Christophe Boissier","doi":"10.1016/j.rhum.2024.04.001","DOIUrl":"10.1016/j.rhum.2024.04.001","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 4","pages":"Pages 421-423"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141053856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"En direct de la SFR : 5 ans de recommandations de la SFR","authors":"Daniel Wendling","doi":"10.1016/j.rhum.2024.05.002","DOIUrl":"10.1016/j.rhum.2024.05.002","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 4","pages":"Pages 532-533"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141414821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arthrose, arthropathies microcristallines et ostéoporose : un point épidémiologique","authors":"Anne-Christine Rat","doi":"10.1016/j.rhum.2024.05.009","DOIUrl":"https://doi.org/10.1016/j.rhum.2024.05.009","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"91 4","pages":"Pages 494-495"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141480354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}